Diabetes mellitus is c hronic disease whic h has been desc ribed as a state of raised blood gluc ose assoc iated with premature mortality. Diabetes is bec oming a world pandemic . Both type 1 and type 2 diabetes are spreading rapidly ac ross the globe. Globally there are already over 1 5 0 million people with diabetes, and this is c onservatively predic ted to double by 2 0 2 5 [ 1 ] . Type 2 diabetes ac c ounts for most of the c urrent and forec asted figures. Less developed c ountries are shouldering most of the burden and, by 2 0 2 5 , one third of all people with diabetes will live in India or China alone [ 1 ] . In addition to these alarming absolute rises in numbers, there is also a worsening trend for the disease to affec t younger age groups. In developed c ountries the sharpest inc reases affec t the over 6 5 s, unlike the situation in developing c ountries where most new c ases oc c ur in those between 4 4 and 6 5 years of age. Of partic ular c onc ern is the worldwide emergenc e of type 2 diabetes in the very young, inc luding c hildren and adolesc ents. This downward shift, in the age at whic h diabetes develops, has serious implic ations for the development of c omplic ations. Diabetes c omplic ations, inc luding c ardiovasc ular disease ( CVD) , bec ome more probable with the longer duration of diabetes, and are also more likely to develop at an earlier age.
Cardiovascular disease: the number one killer
CVD suc h as c oronary heart disease, c erebrovasc ular disease and peripheral vasc ular disease are a major worldwide public health problem. It is the number one c ause of death in industrialized c ountries. It is also set to overtake infec tious diseases as the most c ommon c ause of death in many parts of the less developed world [ 1 ] .
Although the problems assoc iated with CVD are severe in all parts of the world, differenc es in patterns c an be identified. In China, Japan and many Afric ans c ountries for example, stroke is more c ommon than c oronary heart disease whereas, among Cauc asian populations, c oronary heart disease is more c ommon. In some developed nations, suc h as the USA, Australia and Europe, where c oronary heart disease rates were previously very high, mortality has fallen in rec ent dec ades [ 1 ] . However in other areas suc h as Eastern Europe and the Middle East, the opposite is true. The "top ten" c ountries for both c oronary and c erebrovasc ular disease mortality rates are now mainly from Eastern Europe and the former Soviet Union [ 1 ] .
A ticking time bomb
As c an be seen from the prec eding paragraphs, both diabetes and CVD are major health problems. Sinc e people with diabetes are at inc reased risk of CVD, the two situations when taken together c onstitute a "double jeopardy". People with diabetes are two to four times more likely to develop CVD than people without diabetes, making it the most c ommon c omplic ation of diabetes. When we c onsider that the number of people with diabetes around the world is predic ted to double over the c oming dec ades, the outlook for CVD bec omes even more alarming.
In short, the predic ted esc alation in the prevalenc e of diabetes is likely to c ontribute to a CVD epidemic , partic ularly in the developing world -unless preventive measures are taken as a matter of urgenc y. 
H ow does diabetes lead to cardiovascular disease?
Diabetes predisposes to CVD in a number of ways. People with diabetes are at inc reased risk of atherosc lerosis, and, to make matters worse, atherosc lerosis in people with diabetes is ac c elerated in development, more widespread and more severe.
High blood pressure is also at least twic e as c ommon in people with diabetes, and is also more frequent in people with impaired gluc ose toleranc e [ 3 ] .
Diabetes also has other effec ts on blood vessels, notably the spec ific c omplic ations of mic roangiopathy and neuropathy, together with damage to blood vessel walls. These c omplic ations not only produc e spec ific diabetesrelated problems suc h as retinopathy and nephropathy, but also synergize with atherosc lerosis and hypertension to produc e an ongoing c yc le of blood vessel damage throughout the arterial system, affec ting all sizes of vessel.
The c ausal link between hyperglyc aemia and mic roangiopathy has been emphasized by a number of rec ent c linic al trials, all of whic h show that the mic roangiopathic c omplic ations of diabetes are the most readily preventable with good glyc aemic c ontrol [ 4 , 5 ] . Endothelial dysfunc tion is an important c omponent of both mac roangiopathy and mic roangiopathy, but c an also appear early in the c ourse of diabetes before the onset of detec table vasc ular disease. The presenc e of these additional fac tors helps to explain why people with diabetes suffer more severe c onsequenc es from individual events suc h as heart attac ks and strokes.
The presenc e of c oexisting nerve damage in diabetes c an affec t the ability to feel pain. Thus, c onditions suc h as heart attac k and angina may go unrec ognized bec ause the sufferer feels no pain and the c ondition is "silent".
T he cardiovascular disease triad in diabetes
In prac tic e the most important c linic al manifestations of diabetic vasc ular disease c an be divided into the same three groups:
• those affec ting the c oronary c irc ulation • those affec ting the c erebral c irc ulation • those affec ting the lower limb
Coronary H eart Disease
Angina: When autonomic neuropathy is present, the typic al pain of angina whic h is usually assoc iated with isc hemia may not be experienc ed, leading to silent isc hemia.
Heart attac k: People with type 2 diabetes have the same risk of heart attac k as people without diabetes who have already had a heart attac k [ 6 ] . People with diabetes c an have a heart attac k without even realizing it. Also, sinc e people with diabetes often have widespread vasc ular disease, the c onsequenc es of a heart attac k are often more severe than in people without diabetes, resulting in greater diffic ulty with emergenc y treatments. For these and other reasons, people with type 2 diabetes have a higher risk of death following a heart attac k [ 7 ] .
Sudden death: Men with diabetes are also more prone to sudden death c ompared to other people of a similar age, and this is partic ularly marked in women [ 8 ] .
Heart failure: People with diabetes have a two to three-fold greater risk of heart failure when c ompared with nondiabetic people.
Cerebrovascular Disease
Stoke: Strokes oc c ur twic e as often in people with diabetes and hypertension as in those with hypertension alone [ 8 ] .
Transient isc hemic attac k: Transient isc hemic attac k oc c urs between two and six times more frequently in people with diabetes [ 8 ] .
Dementia: The additive effec ts of multiple small strokes, together with mic roangiopathy affec ting the small blood vessels to the brain, lead to an inc reased likelihood of dementia in people with diabetes.
Peripheral Vascular Disease
Atherosc lerosis of the arteries in the lower limbs together with nerve damage explains the very high risk of lowerlimb amputation in people with diabetes, whic h is inc reased 1 5 -4 0 fold c ompared to the general population [ 8 ] .
The impac t of diabetes is further emphasized by data from USA, where CVD mortality rates are falling in the general population. In men with diabetes they are also falling but to a muc h lesser extent and in women with diabetes the rates go against the trend and c ontinue to rise [ 9 ] .
As we have seen, diabetes c an lead to c ardiovasc ular damage in a number of ways. These proc esses do not develop independently, as eac h may ac c elerate or worsen the others. This means that when people with diabetes develop for example a heart attac k or stroke, the prognosis is worse than for people without diabetes bec ause of the vic ious c yc le c aused by the c ombined vasc ular abnormalities assoc iated with diabetes. Indeed, c ardiovasc ular disease is the leading c ause of death in people with diabetes in developed c ountries [ 8 ] .
W hy the increased risk?
About half of the exc ess risk in diabetes is explained by the fac t that people with diabetes have a higher prevalenc e of many other CVD risk fac tors, suc h as hypertension, disturbanc es of blood fat levels and obesity [ 1 0 ] . These risk fac tors are interrelated and are more prominent in type 2 diabetes than in type 1 .
Diabetes belongs to a spec ial risk c ategory as it so markedly the risk of c ardiovasc ular disease [ 1 1 ] . The United Kingdom Prospec tive Study ( UKPDS) has shown that there is a signific ant linear c orrelation between haemoglobin A1 c and mac rovasc ular events in type 2 diabetes [ 1 2 ] . This is also seen in people with more minor disturbanc es of blood gluc ose metabolism suc h as impaired fasting glyc aemia ( IFG) and impaired gluc ose toleranc e ( IGT) [ 1 3 ] .
People with type 1 diabetes over the 3 0 years have a c oronary heart disease risk similar to people with type 2 diabetes. People with type 1 diabetes who suffer from diabetic nephropathy, regardless of age, should be treated as being at partic ularly high risk.
It is important to emphasize that the presenc e of multiple c ardiovasc ular risk fac tors has a multiplic ative and not an additive effec t upon the inc idenc e of c oronary heart disease in the general population [ 1 4 ] . The situations is even more serious in people with diabetes as, for eac h risk fac tor present, c ardiovasc ular mortality is about thee times greater than in the general population [ 1 5 ] .
Mic roalbuminuria, lipoprotein ( a) , homoc ysteine and Creac tive protein have also been shown to be risk fac tors for c ardiovasc ular disease in people with diabetes [ 1 6 , 1 7 , 1 8 ] .
Due to the higher prevalenc e and impac t of c ardiovasc ular risk fac tors, as well as the role of hyperglyc aemia, people with diabetes without overt c ardiovasc ular c omplic ations merit an intervention against risk fac tors similar to that whic h would normally be provided for individuals with established c ardiovasc ular disease.
Diabetes care and management
The devastating c omplic ations of diabetes, suc h as CVD, kidney failure and blindness, are imposing a huge burden on health c are servic es. It is estimated that diabetes ac c ounts for between 5 % stand 1 0 % of a nation's health budget [ 2 ] . The human and ec onomic c osts of diabetes c ould be signific antly reduc ed by investing in prevention, partic ularly early detec tion, to avoid the onset of diabetic c omplic ations.
There is good evidenc e from a number of rec ent c linic al trials to show that c ontrol of blood pressure, blood lipids and blood gluc ose levels c an all reduc e substantially the risk of CVD events and diabetes-related death [ 1 9 , 2 0 , 2 1 ] . The figures vary ac c ording to the risk fac tor and the design of the study, but the perc entage drops ranging from 3 0 -6 0 % are c learly well within reac h. Despite these findings, a rec ent US study revealed that while c ardiovasc ular disease mortality and partic ularly c oronary heart disease related deaths have dec lined in those without diabetes, in men with diabetes the dec rease has been a modest 1 3 %, while in women with diabetes the rates have ac tually inc reased by 2 3 % [ 9 ] . This suggests that approac hes proven to reduc e c ardiovasc ular disease in people with diabetes are frequently not implemented in c linic al prac tic e.
Targets for c ommon c ardiovasc ular risk fac tors in people with diabetes: Dyslipidaemia:
• Dec rease LDL c holesterol levels ( < 1 1 5 mg/dl or 3 mmol/L)
• Raise HDL c holesterol levels ( > 4 6 mg/dl or 1 .2 mmol/ L)
• Lower triglyc erides ( < 1 5 0 mg/dl or 1 .7 mmol/L) Hypertension:
• Lower blood pressure ( < 1 3 5 /8 5 mm Hg) Hyperglyc aemia:
• Reduc e hyperglyc aemia ( HbA1 c < 7 %) These levels are based on IDF Europe's guidelines [ 2 2 ] .
Onc e diabetes has bec ome established in an individual there is a lot that c an be done to prevent CVD and minimize risk. Onc e CVD has developed, and events suc h as heart attac k or stroke have oc c urred, the aggressive applic ation of modern treatments c an still lead to improved outc omes. Measures suc h as insulin therapy, aspirin, c ertain drugs suc h as ß -bloc kers, hypolipaemic agents ( statins, fibrates or a c ombination of the two) , angiotensin c onverting enzyme ( ACE) inhibitors, AT1 rec eptor bloc kers, c alc ium c hannel bloc kers, c lot dissolving agents, and modern revasc ularization proc edures c an all improve outc ome.
The major diffic ulty here is the provision of adequate resourc es, partic ularly in poorer c ountries. It also has to be remembered that many people may not survive an ac ute event to rec eive the benefit of these treatments. This serves to emphasize the importanc e of prevention, inc luding both the primary prevention of diabetes and the sec ondary prevention of CVD in people who have already developed diabetes. Investment in primary and sec ondary prevention strategies is potentially the most effec tive measure in the long term, in both human and ec onomic terms.
The major lifestyle measures -diet and physic al ac tivity -need to be emphasized in national diabetes and CVD programmes. These programmes c an be integrated or linked with other health or environmental programmes. The message should be transmitted to all sec tors of soc iety, and ideally should be addressed to whole populations rather than just to high-risk groups.
Engagement of governments is essential if these programmes are to have maximal effec t, and this is where the influential role of international organizations suc h as IDF and WHO bec omes very important. 
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